List of Excipients in Branded Drug CETIRIZINE HCL 10 MG ALL DAY ALLERGY RELIEF

Generic Drugs Containing CETIRIZINE HCL 10 MG ALL DAY ALLERGY RELIEF

Company	Ingredient	NDC	Excipient
Freds Inc	cetirizine hydrochloride	55315-129	LACTOSE MONOHYDRATE
Freds Inc	cetirizine hydrochloride	55315-129	MAGNESIUM STEARATE
Freds Inc	cetirizine hydrochloride	55315-129	POLYETHYLENE GLYCOL
Freds Inc	cetirizine hydrochloride	55315-129	POLYVINYL ALCOHOL
Freds Inc	cetirizine hydrochloride	55315-129	POVIDONE

What are the Most Frequently-Used Excipients in CETIRIZINE HCL 10 MG ALL DAY ALLERGY RELIEF?

# Of NDCs	Excipient
1	LACTOSE MONOHYDRATE
1	MAGNESIUM STEARATE
1	POLYETHYLENE GLYCOL
1	POLYVINYL ALCOHOL
1	POVIDONE

Cetirizine HCl 10 mg All Day Allergy Relief: Excipient Strategy and Commercial Opportunities

Last updated: August 12, 2026

Cetirizine hydrochloride 10 mg is a mature, low-cost second-generation antihistamine with broad OTC availability in the United States. The active ingredient has limited exclusivity value; commercial differentiation depends on dosage form, onset messaging, tolerability, packaging, channel economics, and formulation execution.

The strongest excipient opportunities are in orally disintegrating tablets, chewables, liquids, multilayer tablets, taste-masked products, and formulations designed for consumers who have difficulty swallowing conventional tablets. Basic immediate-release 10 mg tablets have low technical barriers and face intense private-label competition.

What is the regulatory status of cetirizine HCl 10 mg?

Cetirizine hydrochloride is an OTC antihistamine used for temporary relief of symptoms associated with hay fever and other upper-respiratory allergies, including sneezing, runny nose, itchy or watery eyes, and itching of the nose or throat. The standard adult and pediatric dose for consumers aged six years and older is 10 mg once daily, although some products use a 5 mg dose for certain age groups or patients with reduced renal function.[1,2]

The product category is regulated under the FDA OTC monograph framework for antihistamine drug products. Cetirizine is also marketed through abbreviated new drug applications and legacy branded products. FDA approval of the OTC switch for Zyrtec expanded consumer access and accelerated the transition of cetirizine from a prescription-led product to a mass-market allergy medicine.[3]

Attribute	Commercial position
Active ingredient	Cetirizine hydrochloride
Common strength	10 mg
Therapeutic class	Second-generation H1 antihistamine
Primary dosage forms	Tablets, chewables, orally disintegrating tablets, solutions, syrups
Typical dosing	Once daily
U.S. regulatory route	OTC monograph and approved product pathways
Prescription status	Broadly OTC in the U.S.
Core patent position	Mature and generally off-patent
Main competitive issue	Price and retail placement
Main formulation opportunity	Easier administration and improved taste

The phrase “All Day Allergy Relief” is generally a consumer-facing indication or marketing statement rather than a separate active-ingredient innovation. The exact label, inactive ingredients, manufacturer, and National Drug Code depend on the specific product.

What excipients are used in cetirizine HCl 10 mg tablets?

Conventional cetirizine HCl 10 mg tablets typically use a direct-compression or granulation platform. Common excipient classes include fillers, binders, disintegrants, glidants, lubricants, and film-coating materials.

A representative immediate-release composition may contain:

Formulation function	Candidate excipients	Commercial purpose
Diluent	Microcrystalline cellulose, lactose monohydrate, mannitol, dibasic calcium phosphate	Controls tablet weight and compression
Binder	Povidone, copovidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule or tablet strength
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Promotes tablet breakup
Glidant	Colloidal silicon dioxide	Improves powder flow
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces sticking and ejection force
Film former	Hypromellose, polyvinyl alcohol	Improves appearance and handling
Plasticizer	Polyethylene glycol, triethyl citrate	Improves coating flexibility
Opacifier or colorant	Titanium dioxide, iron oxides, approved lakes	Supports product identification
Sweetener or flavor	Sucralose, aspartame, acesulfame potassium, flavor systems	Supports chewable or ODT use

The active ingredient is commonly used at a relatively low percentage of total tablet weight. This creates formulation flexibility but also raises blend-uniformity and segregation risks during scale-up. A formulation with low drug loading requires controlled particle-size distribution, appropriate premixing, and validated content uniformity.

FDA’s Inactive Ingredient Database is the primary reference for assessing prior use of excipients in approved dosage forms and routes. It does not replace product-specific safety, quality, or regulatory assessment.[4]

Which excipient platform is best for a 10 mg cetirizine product?

The optimal platform depends on the target channel and consumer segment. A standard tablet has the lowest cost. An orally disintegrating tablet or chewable has better differentiation but introduces taste, moisture, and packaging challenges.

Immediate-release film-coated tablet

This is the lowest-risk and lowest-cost platform. It is appropriate for mass retail, club stores, pharmacy chains, and private-label programs.

Key development priorities are:

• Consistent disintegration under pharmacopoeial conditions.
• Low tablet weight variation.
• Robust content uniformity at 10 mg strength.
• Low friability.
• Stable dissolution across packaging configurations.
• Compatibility with high-speed compression.
• Efficient film coating without slowing release.

A lactose-MCC or MCC-mannitol filler system can provide acceptable compactability. Crospovidone is often attractive where rapid tablet breakup is required without excessive swelling. Magnesium stearate levels should be controlled because over-lubrication can reduce tablet tensile strength and slow dissolution.

Orally disintegrating tablet

ODTs provide the clearest commercial route for excipient-led differentiation. They target consumers who have difficulty swallowing tablets, need convenient dosing without water, or prefer a faster-dissolving format.

A typical ODT platform may use:

• Mannitol for mouthfeel and cooling sensation.
• Crospovidone for rapid disintegration.
• Low-substituted hydroxypropyl cellulose or croscarmellose sodium for structure and breakup.
• Sucralose or acesulfame potassium for sweetness.
• Flavor masking for cetirizine’s bitter or medicinal taste.
• Colloidal silicon dioxide for flow.
• A low-moisture blister or high-barrier bottle.

The primary development risk is not disintegration. It is the balance between rapid oral dispersion, mechanical strength, hygroscopicity, and taste. Cetirizine ODTs can become commercially weak if they require excessive packaging protection or leave a bitter aftertaste.

Chewable tablet

Chewables can target families, travel use, and consumers who prefer a tablet over liquid medicine. A mannitol-based system is often suitable because it supports a cleaner mouthfeel than some lactose-heavy formulations.

Chewables need:

• Strong taste masking.
• Low chalkiness.
• Adequate fracture behavior.
• Controlled hardness.
• Low friability during transport.
• Flavor stability over shelf life.

A compressed chewable with a lipid or polymeric taste-masking layer around cetirizine particles may offer a more defensible formulation position than a simple sweetened tablet.

Oral solution or syrup

Liquid formulations address pediatric use and swallowing difficulty but have higher manufacturing, packaging, and microbiological-control costs. Candidate excipients include sorbitol, glycerin, propylene glycol, sodium citrate or citric acid buffers, sodium benzoate or potassium sorbate, sweeteners, and flavors.

The commercial tradeoff is clear:

Benefit	Cost or risk
Flexible dosing	More complex measuring and labeling
Pediatric positioning	Higher microbiological risk
Easier swallowing	Larger package and shipping cost
Taste customization	Preservative and flavor compatibility
Potential pharmacy or grocery differentiation	Dose-uniformity and stability requirements

Liquid products require careful control of preservative effectiveness, pH, container closure, dosing-device accuracy, and extractables and leachables.

What formulation patents could protect cetirizine HCl 10 mg?

The basic cetirizine molecule and ordinary 10 mg immediate-release tablet are weak patent targets because the product is mature and widely commercialized. New patent value would more likely arise from a specific technical solution.

Potentially protectable areas include:

1. A defined taste-masking coating around cetirizine particles.
2. A rapidly disintegrating ODT with specified mechanical strength and moisture limits.
3. A low-hygroscopicity formulation with a defined excipient ratio.
4. A liquid formulation with improved preservative stability.
5. A pediatric formulation with a calibrated dosing device.
6. A multilayer tablet separating cetirizine from incompatible excipients.
7. A process that improves blend uniformity or reduces segregation.
8. A high-barrier package combined with a moisture-sensitive ODT.
9. A formulation that limits a specific impurity or degradation pathway.
10. A novel combination product, subject to FDA monograph and combination-drug requirements.

Patent claims should focus on measurable composition or performance limits. Broad claims covering “cetirizine with a pharmaceutically acceptable excipient” would face substantial validity and obviousness risk.

A practical formulation patent would specify parameters such as:

• Cetirizine particle-size distribution.
• Excipient concentration ranges.
• Disintegration time.
• Dissolution profile.
• Water activity.
• Moisture uptake.
• Taste-masking performance.
• Tablet tensile strength.
• Stability impurity thresholds.

When does cetirizine lose exclusivity?

Cetirizine is a mature off-patent active ingredient. The original branded product protections and prescription-era exclusivity have expired, and generic and private-label products have been widely available for years. The relevant commercial question is no longer loss of active-ingredient exclusivity. It is whether a new dosage form, formulation, label, or package can create incremental protection.

Protection type	Position for standard cetirizine 10 mg
Active-ingredient patent	Expired or commercially exhausted
Standard tablet exclusivity	No meaningful current exclusivity
OTC monograph position	Available to qualifying products
Formulation patent	Possible for a genuinely novel formulation
Method-of-use patent	Limited scope for ordinary allergy indications
Trade dress	Potentially useful but narrow
Brand recognition	Available through marketing investment
Regulatory exclusivity	Generally not a meaningful barrier for standard products

The FDA Orange Book is most relevant to approved prescription products and listed patents. A standard OTC cetirizine product should not be assumed to have an Orange Book patent barrier comparable to a newer prescription drug.[5]

What is the Orange Book and Paragraph IV status of cetirizine?

Cetirizine has no meaningful current Paragraph IV risk profile for the ordinary OTC 10 mg tablet because the active ingredient is already genericized and the central market is not protected by an unexpired pioneer patent.

Paragraph IV activity could still matter if a company develops an approved prescription or specialty formulation with unexpired patents. A generic applicant challenging such patents could file a Paragraph IV certification, but that scenario would concern the specific listed formulation or use patent, not ordinary cetirizine HCl 10 mg.

For commercial diligence, the relevant checks are:

• FDA Orange Book patent listings for the exact reference product.
• FDA Drugs@FDA records.
• FDA OTC monograph compliance.
• DailyMed inactive-ingredient and labeling records.
• USP-NF requirements for excipient and finished-product quality.
• Patent databases for formulation-specific claims.
• State substitution and labeling requirements.

Which companies compete in the cetirizine 10 mg market?

Competition comes from branded manufacturers, national generic companies, private-label retailers, and online sellers. Major commercial entities associated with the cetirizine category have included Johnson & Johnson consumer-health businesses, Perrigo, Teva, Dr. Reddy’s, CVS, Walmart, Target, Amazon, Costco, and other store-brand manufacturers or suppliers.

The competitive landscape is segmented rather than controlled by a single patent holder.

Segment	Competitive basis
National brand	Recognition, advertising, shelf position
Store brand	Lowest price and retailer distribution
Premium formulation	ODT, chewable, liquid, flavor, packaging
Pediatric product	Dose flexibility, flavor, measuring device
E-commerce	Search ranking, multipack value, subscription
Pharmacy channel	Generic substitution and pharmacist recommendation
Club channel	Large count bottles and low unit cost

Revenue exposure for a new entrant is therefore more sensitive to distribution and cost of goods than to patent exclusivity. A formulation with a 10% higher unit cost may fail in a commodity tablet segment unless it obtains a retail premium or reaches a consumer group underserved by conventional tablets.

What commercial opportunities exist for cetirizine excipients?

The highest-probability opportunities are formulation extensions that improve user experience while retaining once-daily convenience.

1. Premium ODT

A rapid-dissolve, low-bitter ODT can support a higher retail price than a conventional tablet. The strongest target groups are travelers, older adults, consumers with dysphagia, and consumers who prefer dosing without water.

Commercial requirements include moisture-protective packaging, a distinctive flavor system, and reliable tablet integrity.

2. Pediatric chewable

A chewable product can compete in the family allergy segment. The formulation must deliver acceptable taste without excessive sugar, dental-health concerns, or artificial flavor intensity.

3. Sugar-free liquid

A sugar-free oral solution using sorbitol, glycerin, and high-intensity sweeteners can target pediatric and adult consumers who avoid sucrose. The product needs a stable preservative system and a dosing syringe or calibrated cup.

4. Senior-friendly packaging

Packaging is an underused opportunity. Easy-open bottles, large-print labels, unit-dose blister cards, and high-contrast dose markings can differentiate a standard active ingredient without changing the pharmacology.

5. Clean-label positioning

Some consumers prefer lactose-free, dye-free, gelatin-free, gluten-free, or vegan-compatible products. These claims require controlled supplier qualification and substantiation. They can support retailer-specific or direct-to-consumer products, although they do not create strong patent exclusivity.

6. Combination allergy products

Cetirizine can be combined with other allergy-relief ingredients, but combination products introduce regulatory and clinical complexity. A product combining an antihistamine with a decongestant may carry additional cardiovascular warnings, labeling constraints, and competitive pressure from established brands.

How strong is the patent estate for a new cetirizine formulation?

The patent estate is weak for a conventional tablet and potentially moderate for a technically differentiated dosage form.

Product concept	Patent strength	Regulatory complexity	Commercial potential
Standard 10 mg tablet	Low	Low	High volume, low margin
Film-coated tablet with ordinary excipients	Low	Low	Limited differentiation
ODT with taste masking	Moderate	Moderate	Strong
Pediatric chewable	Moderate	Moderate	Strong
Preserved oral solution	Low to moderate	Moderate	Moderate
Novel delivery system	Moderate to strong	High	Uncertain
Combination product	Moderate	High	Potentially strong
Packaging-only innovation	Low	Low to moderate	Channel-dependent

The best intellectual-property strategy combines a narrow formulation patent with trade secrets covering flavor masking, coating process, particle engineering, compression settings, and packaging configuration. Trade-secret protection may be more durable than a narrow patent for process conditions and sensory optimization.

What manufacturing and IP barriers affect cetirizine products?

Manufacturing barriers are manageable for standard tablets but increase for ODTs and liquids.

Standard tablets

The main risks are:

• Low-dose blend uniformity.
• Powder segregation.
• Lubricant overuse.
• Tablet capping and picking.
• Coating variability.
• Dissolution drift during scale-up.

ODTs

The main risks are:

• Moisture uptake.
• Soft or friable tablets.
• Taste-masking failure.
• Flavor migration.
• Blister seal integrity.
• Shortened shelf life.

Liquids

The main risks are:

• Preservative loss.
• Microbial growth.
• pH drift.
• Sedimentation or crystallization.
• Dosing-device variability.
• Container interaction.

A contract development and manufacturing organization with ODT compression, taste masking, and high-barrier packaging capabilities can create a commercial advantage even when the active ingredient is widely available.

How should a company prioritize cetirizine formulation investment?

A staged strategy is preferable:

1. Launch a cost-optimized standard tablet where volume and retailer access are the priority.
2. Develop an ODT or chewable extension for premium positioning.
3. Build a separate pediatric liquid only if distribution supports the added manufacturing and quality burden.
4. Protect the differentiated formulation through composition, process, and packaging claims.
5. Use proprietary taste-masking and stability data as trade secrets.
6. Avoid relying on the phrase “all day” as the main differentiator because once-daily dosing is already associated with cetirizine products.
7. Secure retailer or pharmacy distribution before committing to a high-cost formulation platform.

Key Takeaways

• Cetirizine HCl 10 mg is an off-patent, high-volume OTC antihistamine.
• Standard tablets face intense price competition and have limited patent value.
• ODTs, chewables, pediatric liquids, and consumer-friendly packaging offer the clearest commercial opportunities.
• Taste masking, moisture control, preservative stability, and tablet robustness are the central formulation challenges.
• A meaningful patent strategy should claim defined composition and performance parameters, not generic excipient combinations.
• Orange Book and Paragraph IV barriers are generally immaterial for ordinary cetirizine 10 mg products.
• Commercial success depends primarily on retail access, manufacturing cost, packaging, brand position, and formulation convenience.
• The most attractive excipient-led product is a low-bitter, moisture-stable ODT or chewable with premium packaging.

FAQs

Can cetirizine HCl 10 mg be reformulated as a sugar-free chewable?

Yes. A sugar-free chewable can use mannitol, sorbitol, sucralose, acesulfame potassium, and a flavor system. The main development issue is achieving acceptable mouthfeel without excessive cooling, chalkiness, or bitterness.

Is lactose-free cetirizine commercially attractive?

Yes, particularly for private-label, clean-label, and direct-to-consumer channels. Lactose-free positioning requires replacement of lactose with alternatives such as microcrystalline cellulose, mannitol, or dibasic calcium phosphate and requires appropriate label substantiation.

Does cetirizine require a taste-masking coating?

A conventional swallowed film-coated tablet may not require sophisticated taste masking. ODTs, chewables, and liquids generally do. Taste masking can use polymer coatings, ion-exchange resins, lipid systems, or optimized sweetener-flavor combinations.

Can excipients create market exclusivity for cetirizine?

Excipients alone rarely create broad exclusivity. A novel excipient combination may support patent claims when it produces a defined technical result, such as rapid disintegration, improved stability, or reduced bitterness. The protection is usually narrower than active-ingredient exclusivity.

What is the most defensible commercial format for a new cetirizine product?

A moisture-stable, low-bitter ODT with convenient packaging is generally more defensible than another conventional 10 mg tablet. Its value depends on demonstrable consumer benefit, scalable manufacturing, and a retail channel willing to support a premium.

References

1. U.S. Food and Drug Administration. (n.d.). DailyMed: Cetirizine hydrochloride tablet labeling. National Library of Medicine.

2. U.S. Food and Drug Administration. (2024). Code of Federal Regulations, Title 21, Part 341: Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use. https://www.ecfr.gov/

3. U.S. Food and Drug Administration. (2007). FDA approves over-the-counter Zyrtec for allergies. https://www.fda.gov/

4. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.fda.gov/drugs/drug-approvals-and-databases/inactive-ingredients-database-download

5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book